Enchi Liu

EVALUATION OF CEREBRAL GRAY MATTER AND PONS AS REFERENCE REGIONS FOR AMYLOID PET: RESULTS FROM A BAPINEUZUMAB SUBCUTANEOUS PHASE 2 TRIAL

Jianing Di, Enchi Liu, Kevin Booth, 2014, Alzheimer's & Dementia.

Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns

Norbert Schuff, Robert C. Green, Andrew J. Saykin, 2017 .

Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans

Norbert Schuff, Adrian Preda, John Kornak, 2012, Proceedings of the National Academy of Sciences.

Building a roadmap for developing combination therapies for Alzheimer’s disease

Steven Potkin, Michael Krams, Yaning Wang, 2015, Expert review of neurotherapeutics.

Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.

Philip D. Harvey, Philip D Harvey, Keith Wesnes, 2017, Innovations in clinical neuroscience.

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Nick C Fox, Robert Koeppe, Jianing Di, 2015, Neurology.

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

Nick C Fox, Jerome Barakos, Donatella Tampieri, 2012, The Lancet Neurology.